发明名称 |
USE OF CK2 INHIBITOR FOR THE TREATMENT AND CHEMOSENSIBILIZATION OF REFRACTORY TUMORS TO ANTICANCER DRUGS |
摘要 |
<p num="1">The present invention relates to a pharmaceutical combination that includes a casein kinase 2 phosphorylation inhibitor (called p15) and cytostatics used in cancer chemotherapy, which are administered simultaneously, separately or sequentially. The preferred cytostatics are platinums, taxans, vinca alkaloids, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomycin C, imatinib, iressa and velcade (bortezomib). Synergy between peptide p15 and the anticancer chemical compounds means that the effective concentration of each cytostatic in the combination is between 1 and 2 orders of magnitude less than that corresponding to cytostatics alone. Consequently, the combination described in the invention has a much lower toxicity than that reported for anticancer cytostatics, which represents a crucial advantage in their use in cancer treatment. Additionally, administered sequentially, the combination gives rise to the chemosensitization of refractory tumours to the cytostatics mentioned by means of pre-treatment with peptide p15.</p> |
申请公布号 |
CA2642943(A1) |
申请公布日期 |
2007.09.07 |
申请号 |
CA20072642943 |
申请日期 |
2007.02.28 |
申请人 |
CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA;BIOREC B.V. |
发明人 |
PEREA RODRIGUEZ, SILVIO ERNESTO;BESADA PEREZ, VLADIMIR;CASTELLANOS SERRA, LILA ROSA;GIL VALDES, JEOVANIS;PERERA NEGRIN, YASSER;BETANCOURT NUNEZ, LAZARO HIRAM;RAMOS GOMEZ, YASSEL;GONZALEZ LOPEZ, LUIS JAVIER;FERNANDEZ DE COSSIO DORTA DUQUE, JORGE;RODRIGUEZ ULLOA, ARIELIS;SANCHEZ PUENTE, ANIEL;ALONSO, DANIEL FERNANDO;ACEVEDO CASTRO, BORIS ERNESTO;GOMEZ, DANIEL EDUARDO |
分类号 |
A61K38/08;A61K31/00;A61P35/00 |
主分类号 |
A61K38/08 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|